CD19 and leukemia: While strategies based on dual-antigen targeting are beginning to emerge (6), the apparent superiority of CD19 as a leukemia-associated antigen fuels interest in alternative CD19-directed therapeutics recognizing epitopes other than the commonly used FMC63 (7, 8).